EUCTR2012-002911-24-AT进行中（未招募）不适用
Protocol H9X-MC-GBDGA Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide with Placebo in Patients with Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AWARD-8: Assessment of Weekly AdministRation of LY2189265 in Diabetes – 8) - AWARD-8
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 285
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Type 2 diabetes (based on the World Health Organization’s [WHO] diagnostic criteria)
- •a. Not optimally controlled on diet and exercise and a stable dose of sulfonylurea that is at least 50% of the maximum approved dose per the local label for at least 3 months prior to the first study visit
- •b. HbA1c value of =7.5% and =9.5%
- •2. Accept continued treatment with sulfonylurea therapy, throughout the trial, as required per protocol
- •3. Men and nonpregnant women aged =18 years - only in Austria: Men or nonpregnant women aged =18 years of age and = 80 years of age
- •4. Stable weight (±5%) =3 months prior to screening
- •5. BMI =45 kg/m2
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 240
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 45
排除标准
- •1. Type 1 diabetes mellitus
- •2. Have been treated with ANY other antihyperglycemic medications (other than sulfonylurea) at the time of the first study visit or within 3 months of the first study visit
- •3. Have used insulin therapy (outside of pregnancy) any time in the past 2 years, except for short-term treatment of acute conditions, and up to a maximum of 4 weeks. Any insulin within 3 months prior to the first study visit is exclusionary.
- •4. Have been treated with drugs that promote weight loss within 3 months of the first study visit
- •5. Are receiving chronic (>14 days) systemic glucocorticoid therapy or have received such therapy within the 4 weeks immediately prior to the first study visit
- •6. Have had any of the following CV conditions within 2 months prior to the first study visit: acute myocardial infarction, New York Heart Association (NYHA) Class III or Class IV heart failure, or cerebrovascular accident (stroke)
- •7. Have a known clinically significant gastric emptying abnormality (eg, severe diabetic gastroparesis or gastric outlet obstruction) or have undergone gastric bypass (bariatric) surgery or restrictive bariatric surgery (eg, Lap-Band®)
- •8. Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or alanine transaminase (ALT) level =2.5 times the upper limit of the reference range
- •9. Have a history of chronic pancreatitis or acute idiopathic pancreatitis, or were diagnosed with any type of acute pancreatitis
- •10. Have an estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2
- •11. Have any self or family history of type 2A or type 2B multiple endocrine neoplasia (MEN 2A or 2B) in the absence of known C-cell hyperplasia (this exclusion includes those patients with a family history of MEN 2A or 2B, whose family history for the syndrome is RET negative; the only exception for this exclusion will be for patients whose family members with MEN 2A or 2B have a known RET mutation and the potential patient for the study is negative for that RET mutation)
- •12. Have any self or family history of medullary C-cell hyperplasia, focal hyperplasia, carcinoma (including sporadic, familial or part of MEN 2A or 2B syndrome)
研究者
相似试验
进行中（未招募）
不适用
A study of dulaglutide compared to placebo in patients receiving sulfonylurea therapy with type 2 diabetesDiabetes Mellitus, Type 2MedDRA version: 14.1Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-002911-24-SIEli Lilly and Company285
进行中（未招募）
1 期
Protocol H9X-MC-GBGE(a)A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus (AWARD-10: Assessment of Weekly AdministRation of LY2189265 in Diabetes ? 10)MedDRA version: 18.0Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 DiabetesEUCTR2015-002095-24-ESIlly, S.A.357
进行中（未招募）
1 期
Protocol H9X-MC-GBGE(b)A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus (AWARD-10: Assessment of Weekly AdministRation of LY2189265 in Diabetes – 10)MedDRA version: 19.0Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 DiabetesEUCTR2015-002095-24-HUEli Lilly and Company426
进行中（未招募）
1 期
Protocol H9X-MC-GBGE(b)A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus (AWARD-10: Assessment of Weekly AdministRation of LY2189265 in Diabetes – 10)Type 2 DiabetesEUCTR2015-002095-24-CZEli LIlly and Company426
进行中（未招募）
1 期
Protocol H9X-MC-GBGE(b)A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus (AWARD-10: Assessment of Weekly AdministRation of LY2189265 in Diabetes – 10)Type 2 DiabetesEUCTR2015-002095-24-ATEli Lilly and Company426